Document is current

Documents that mention this clinical trial

Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054

Documents that mention this clinical trial

Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
https://doi.org/10.1007/s13555-023-01012-z

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
https://doi.org/10.1007/s40257-020-00555-7

Documents that mention this clinical trial

SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.6730

Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00743-7

Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054

Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2
https://doi.org/10.1007/s13555-026-01708-y

AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.2983

THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials
https://doi.org/10.1136/annrheumdis-2018-eular.6782

AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders
https://doi.org/10.1136/annrheumdis-2018-eular.6758

Documents that mention this clinical trial

Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
https://doi.org/10.1136/rmdopen-2020-001217

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064

Documents that mention this clinical trial

Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study ^{(Pre-results)}
https://doi.org/10.1136/annrheumdis-2018-213328

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064

Documents that mention this clinical trial

Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054

Documents that mention this clinical trial

Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468

AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
https://doi.org/10.1136/annrheumdis-2022-eular.28

OP0239 PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
https://doi.org/10.1136/annrheumdis-2021-eular.62

POS0296 INTEGRATED SAFETY ANALYSIS OF TOFACITINIB IN ANKYLOSING SPONDYLITIS CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.2076

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/annrheumdis-2020-219601

Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
https://doi.org/10.1136/annrheumdis-2016-210322

THU0352 Tofacitinib treatment is associated with attainment of the minimally important reduction in axial mri inflammation in patients with ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2017-eular.2447

Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
https://doi.org/10.1136/rmdopen-2022-002253

SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.3247

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial
https://doi.org/10.1007/s40744-023-00564-y

AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C‑REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.2118

Documents that mention this clinical trial

Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054